Comparative Pharmacology
Head-to-head clinical analysis: AZO GANTRISIN versus GANTANOL DS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZO GANTRISIN versus GANTANOL DS.
AZO GANTRISIN vs GANTANOL-DS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfamethoxazole is a competitive inhibitor of dihydropteroate synthase, blocking bacterial folic acid synthesis. Phenazopyridine is an azo dye with local analgesic effects on urinary tract mucosa.
Sulfamethoxazole is a sulfonamide that inhibits bacterial dihydrofolate synthesis by competing with para-aminobenzoic acid, thereby blocking folate synthesis. Trimethoprim inhibits bacterial dihydrofolate reductase, converting dihydrofolate to tetrahydrofolate. This sequential blockade produces bactericidal activity.
AZO GANTRISIN (phenazopyridine 100 mg / sulfisoxazole 500 mg): 2 tablets orally 4 times daily for 2 days, then 1 tablet 4 times daily for up to 5 days.
2 g (DS strength: 2 g sulfamethoxazole/400 mg trimethoprim) orally every 12 hours for 14-21 days for Pneumocystis jirovecii pneumonia.
None Documented
None Documented
Sulfamethoxazole: 9-12 hours (adults with normal renal function), prolonged to 20-50 hours in renal impairment; trimethoprim component: 8-11 hours. Clinical context: dosing interval adjusted based on CrCl.
10-12 hours (sulfamethoxazole component); prolonged in renal impairment (up to 30 hours with CrCl <15 mL/min).
Renal: 70-100% (sulfamethoxazole and metabolites; 15-30% as unchanged drug; remainder as acetylated and glucuronide conjugates). Biliary/fecal: <3%.
Primarily renal (70-100%) as unchanged drug and inactive metabolites (sulfamethoxazole N4-acetyl and glucuronide conjugates); <5% biliary/fecal.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic